Signal was established to develop a new generation of small molecule pharmaceuticals based on recent discoveries about the way genes are regulated. The company's products used gene control — essentially turning genes on and off — to treat inflammatory diseases, viral infections, and neurobiological disorders. The company was acquired by Celgene in September 2000.